REZZAYO
Peakrezafungin
NDAINTRAVENOUSPOWDERPriority Review
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REZZAYO (rezafungin) is an intravenous echinocandin antifungal approved in March 2023 for the treatment of invasive fungal infections. It represents a novel once-weekly dosing option in the echinocandin class, offering improved convenience over existing daily-dosing alternatives. The drug works by inhibiting fungal cell wall synthesis through beta-glucan synthase inhibition.
$0.061MPart D
Peak12.0 years to LOEEarly-stage commercial performance with minimal Part D penetration suggests significant growth opportunity; brand and medical teams are likely scaling rapidly to capture market share in hospital formularies.
Mechanism of Action
Pharmacologic Class:
Echinocandin Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Safety and Pharmacokinetics of Rezafungin
Started Dec 2019
14 enrolled
Fungal Infection
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
Started Oct 2018
199 enrolled
CandidemiaMycosesFungal Infection+1 more
Career Relevance
REZZAYO is a newly approved hospital-focused antifungal with significant whitespace in a mature market, creating early-stage commercial roles in field sales, hospital relations, and formulary access. The once-weekly dosing advantage and long patent protection (12+ years) offer career stability and opportunity to shape market adoption during peak growth phase.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.